🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Practo delivers 3,500 Cr GMV in FY24; narrows EBITDA losses by 82%

EntrackrEntrackr · 11m ago
Practo delivers 3,500 Cr GMV in FY24; narrows EBITDA losses by 82%
Medial

Practo surpassed a GMV (gross merchandise value) of over Rs 3,500 crore in the fiscal year ending March 2024. The company also recorded a 22% year-on-year increase in operating revenue, while operating EBITDA losses reduced by 82% during FY24. Practo’s revenue from operations increased to Rs 240 crore in FY24, reflecting a 22% increase when compared to FY23, the company’s press release shows. Practo helps patients find and connect with the right healthcare providers. It is a platform to find quality & verified healthcare services enabling patients to make informed decisions through an array of processes such as audits of facilities, verification of doctors credentials, merit-based scoring system for providers, patient reviews etc. It also provides software for hospitals and clinics to improve the efficiency of facilities. According to the blog post on the company’s website, it has served over 54 million patients across 642 cities and has done more than 600 healthcare establishment (hospital) audits during the previous fiscal. Practo’s focused approach to its core India business resulted in a 68% CAGR (compound annual growth rate) between FY22 and FY24, while its contribution margin improved significantly, rising from -1% in FY22 to 40% in FY24, according to the press release. “Our goal has always been to improve healthcare outcomes while building a sustainable business. Our sharp focus on the core business has driven exceptional results. Practo is excited to continue this momentum, with ambitious plans for growth with profitability in the coming year”, Shashank ND, Co-founder and CEO, of Practo, added. The growth and controlled expenditure helped Practo to reduce its EBIDTA losses by 82% to Rs 17 crore in FY24 from Rs 99.4 crore in FY23. As per the company, the last quarter (Q4) of FY24 was profitable and claimed profitability over the preceding 12 months ending September 2024. Practo is also exploring global expansion to extend its healthcare services beyond India. Practo has raised a total of $179 million to date from investors including Peak XV Partners, Matrix Partners (Z47), Tencent, and AIA. It competes with Pristyn Care-owned Lybrate, Medibuddy, and Healthians, among others.

Related News

Exclusive: Unacademy narrows EBITDA losses by 38% in FY25, reports Rs 826 Cr income

EntrackrEntrackr · 3m ago
Exclusive: Unacademy narrows EBITDA losses by 38% in FY25, reports Rs 826 Cr income
Medial

Unacademy’s total revenue decreased 16% year on year to Rs 826.3 crore in FY25, compared to Rs 988 crore in FY24, according to the internal document reviewed by Entrackr. Despite the year-on-year decrease in total revenue, edtech unicorn Unacademy managed to reduce its EBITDA losses by 37.6% year-on-year in the fiscal year ending March 2025. Moreover, the SoftBank-backed firm also reduced its net losses by 31% year-on-year to Rs 436 crore in FY25. The firm’s EBITDA loss was Rs 305 crore, down from Rs 489 crore in FY24, a 38% reduction due to cost optimization measures. As of March 2025, Unacademy had a cash and cash equivalent balance of Rs 1,238 crore. Recently, Unacademy elevated Sumit Jain, co-founder and head of its Graphy subsidiary, as CEO of its flagship Test Prep business.

Medibuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37%

EntrackrEntrackr · 5d ago
Medibuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37%
Medial

MediBuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37% Following more than 2X growth in the fiscal year ending March 2024, digital healthcare platform MediBuddy reported modest growth in its operating scale in FY25, while managing to narrow its losses by 37% during the period. MediBuddy's operating revenue grew 12.3% year-on-year to Rs 724.6 crore in FY25 from Rs 645.4 crore in the previous fiscal year (FY24), according to the company's annual financial statements filed with the Registrar of Companies (RoC). MediBuddy, a digital healthcare platform, provides online and offline medical consultations, medicine delivery, lab tests, surgeries, and insurance services, with revenue from these forming the primary source of income at Rs 722 crore, supplemented by Rs 2.5 crore from other operating sources. The company also earned Rs 18.42 crore from non-operating sources, including interest on fixed deposits and current investments, written-off liabilities, and other miscellaneous income, pushing its total income to Rs 743 crore in FY25. On expenses, the cost of materials was the largest at 38% of total expenses, standing at Rs 333 crore. Employee benefits expenses rose marginally by 8% to Rs 176.8 crore, including Rs 6 crore in ESOP expenses. Sales payout expenses, including commissions to selling agents, fell 7% to Rs 155.47 crore. The company spent Rs 42.5 crore on safety and security and Rs 32.5 crore on IT. Other overheads, including legal and professional fees, advertising, depreciation and amortization, and finance costs, amounted to Rs 138.7 crore. Overall expenses for the Bengaluru-based firm remained flat at Rs 879 crore, with controlled expenditure and a 12% rise in revenue helping to narrow losses by 37% to Rs 137 crore from Rs 215.7 crore in FY24. On a unit basis, MediBuddy spent Rs 1.21 to earn one rupee of operating revenue, with its EBITDA margin improving to -14.19% in FY25 from -25.67% in the previous year, resulting in an EBITDA loss of Rs 103 crore. As of March 2024, MediBuddy's current assets were Rs 395.2 crore, including cash and bank balances of Rs 80 crore. MediBuddy has raised over $190 million to date, last raising $18 million in August 2023 from existing investors Quadria Capital, Lightrock, and TEAMFund. It competes with companies including Pristyn Care-owned Lybrate, Practo, and mFine Tata 1mg.

Exclusive: Practo eyes global markets after 6 profitable quarters; pilots underway in US

EntrackrEntrackr · 4m ago
Exclusive: Practo eyes global markets after 6 profitable quarters; pilots underway in US
Medial

Exclusive: Practo eyes global markets after 6 profitable quarters; pilots underway in US IPO-bound digital health platform Practo has posted its first-ever full-year operating EBITDA in FY25. Entrackr has exclusively learned that the company has also kicked off a pilot in the US, with 50–60 paying customers already signed up. The Bengaluru-based company reported an operating EBITDA of Rs 15 crore in FY25, compared to an EBITDA loss of Rs 17 crore in FY24, according to its latest annual letter accessed by Entrackr. During FY25, Practo’s revenue from operations stood at Rs 234 crore, while its gross merchandise value (GMV) remained steady at Rs 3,500 crore. It also achieved positive cash flows, signaling strong capital discipline. Practo showed steady recovery and cost control in FY24, while FY25 demonstrated its ability to scale sustainably. The company claims to have served over 50 million patients across more than 640 cities, supported by a network of 5 lakh doctors. This tech-led efficiency is rooted in Practo’s core ‘Care Navigation’ business, where gross margins grew at a 30% CAGR over the past three years. Its overall contribution margin rose from 40% in FY24 to 46% in FY25, reflecting a sharper focus on high-margin services and improved operational efficiency. As a result, the company turned around from a Rs 162 crore loss in FY22 to a Rs 15 crore profit in FY25, marking a 109% improvement over three years, according to the figures mentioned in the letter. A key focus area driving this momentum is the company’s investment in AI across its product stack. Practo is using artificial intelligence to improve health outcomes, helping patients navigate care more efficiently and enabling smarter workflows and insights for doctors. The firm said it leverages 40 million structured data points to power these AI-led insights. Reinforcing its focus on quality, Practo became the first Indian digital health firm to publish Patient-Reported Outcome Metrics (PROMs). These metrics showed that 78% of telemedicine users and 80% of physical consultation patients reported recovery within three weeks. These figures, based on self-reported outcomes, include patients who did not follow prescribed treatment plans. Building on this outcomes-driven model, Practo deepened its global presence by launching its consumer-facing platform in the UAE in May 2025. Within weeks, the platform onboarded 50,000 monthly active users and hit a Rs 100 crore GMV annual run rate, as per the letter. The company claims that it is on track to reach 10% annual user penetration in Dubai, signaling strong demand for integrated healthcare discovery tools backed by insurance data and cross-border access between Indian and UAE patients and providers. As part of its broader global expansion strategy, Practo aims to double its international revenue over the next few years, while sustaining profitability and scaling its overall impact.

Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses

EntrackrEntrackr · 5m ago
Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses
Medial

Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses Diagnostics platform Redcliffe Labs has posted a 20% increase in its operating revenue to Rs 419 crore in FY25 from Rs 350 crore in FY24 and managed to narrow its EBITDA losses, as per the company’s press release. Diagnostics platform Redcliffe Labs has posted a 20% increase in its operating revenue to Rs 419 crore in FY25 from Rs 350 crore in FY24, as per the company’s press release. The Gurugram-based firm also managed to reduce its EBITDA losses from -38% to -21% during the same period. Founded by Aditya Kandoi, Redcliffe operates a nationwide network of over 80 labs and claims to have the widest home sample collection footprint in the country. Diagnostic services contributed over 95% of the company’s revenue in FY25, with the rest coming from product sales and other operating income. The company said it diagnosed over 2.5 million cases last fiscal and continues to focus on expanding in underserved regions, with more than 70% of its testing volumes now coming from Tier II cities and beyond. On the profitability front, Redcliffe reported a gross margin of 70% in FY25 and is aiming to expand it to 74% in FY26. It has also set a revenue target of Rs 560 crore for the ongoing fiscal through organic growth and strategic acquisitions. “We are transforming lives and making diagnostics a first-line solution for millions who were previously underserved,” said Kandoi. The company plans to expand its presence to over 300 cities with 150 labs by FY28. According to startup data platform TheKredible, Redcliffe has raised $113 million to date, including a $42 million Series C round led by LeapFrog. It also acquired Bengaluru-based Celara Diagnostics in a $7 million deal. Redcliffe competes with players like PharmEasy-owned Thyrocare, Tata 1mg, and Healthians.

Kirana commerce unicorn ElasticRun narrows losses by 60% in FY25

EntrackrEntrackr · 16d ago
Kirana commerce unicorn ElasticRun narrows losses by 60% in FY25
Medial

ElasticRun, a kirana-commerce and logistics platform, stabilised its scale in the fiscal year ending March 2025 after a sharp contraction in the previous year when its revenue had declined by nearly 49%. The company significantly narrowed its losses during the same period. ElasticRun’s gross revenue (GMV) increased 9% to Rs 2,653 crore in FY25, up from Rs 2,435 crore in FY24, according to its consolidated financial statements sourced from the Registrar of Companies (RoC). ElasticRun generates revenue by providing a distribution network that allows kirana stores to access branded goods. The company leverages logistics and technology to streamline distribution, primarily in rural and semi-urban areas, though its footprint has spread to key cities as well now. Income from traded goods, which forms 82% of the operating revenue, grew 7.4% to Rs 2,172 crore in FY25. Income from services surged 17.5% to Rs 477 crore in FY25. Including other income, the company’s total income stood at Rs 2,766 crore in FY25, compared to Rs 2,545 crore in the previous fiscal. On the expense side, cost of materials was ElasticRun’s largest expense, accounting for 73% of the total expense. To the tune of scale, this cost increased 5.1% to Rs 2,118 crore in FY25. Employee benefit expenses declined 17.2% to Rs 207 crore. Freight, handling and servicing costs rose modestly by 4.8% to Rs 457 crore in FY25. Overall, the company’s total expenses rose marginally by 0.2% to Rs 2,911 crore in FY25, compared to Rs 2,904 crore in FY24. The optimization of costs and improvement in high-margin service revenue enabled ElasticRun to narrow its losses by 60% to Rs 145 crore in FY25 from Rs 360 crore in FY24. Its ROCE and EBITDA margin improved to -16.96% and -8.44% respectively. On a unit basis, ElasticRun spent Rs 1.10 to earn a rupee during the year, improving from Rs 1.19 in FY24. The company recorded cash and bank balances of Rs 643 crore, while its current assets stood at Rs 1,566 crore and total assets at Rs 1,659 crore in FY25. According to TheKredible, ElasticRun has raised a total of $461 million of funding till date, having Prosus and Avataar Ventures as its lead investors who own 21.36% and 18.68% of the company respectively.

Download the medial app to read full posts, comements and news.